Mostrar el registro sencillo del ítem
dc.contributor.author
Perez Lloret, Santiago
dc.contributor.author
Cardinali, Daniel Pedro
dc.date.available
2022-08-12T11:08:23Z
dc.date.issued
2021-04
dc.identifier.citation
Perez Lloret, Santiago; Cardinali, Daniel Pedro; Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease; Frontiers Media; Frontiers in Pharmacology; 12; 4-2021; 1-16
dc.identifier.issn
1663-9812
dc.identifier.uri
http://hdl.handle.net/11336/165321
dc.description.abstract
This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5 mg/day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75% of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Frontiers Media
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
AGING
dc.subject
GLYMPHATIC SYSTEM
dc.subject
MELATONIN
dc.subject
NEURODEGENERATION
dc.subject
OXIDATIVE STRESS
dc.subject
PARKINSON’S DISEASE
dc.subject
SLEEP
dc.subject.classification
Neurociencias
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2022-08-11T13:06:23Z
dc.journal.volume
12
dc.journal.pagination
1-16
dc.journal.pais
Suiza
dc.journal.ciudad
Laussane
dc.description.fil
Fil: Perez Lloret, Santiago. Universidad Abierta Interamericana. Secretaría de Investigación. Centro de Altos Estudios En Ciencias Humanas y de la Salud - Sede Buenos Aires.; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina
dc.description.fil
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.journal.title
Frontiers in Pharmacology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fphar.2021.650597
Archivos asociados